July 23, 2012
The rate of new HIV infections among black men who have sex with men (MSM) in the United States, particularly younger men, is high and suggests the need for prevention programs specifically tailored to this population, according to initial findings from the HPTN 061 study. The preliminary results were presented today at the XIX International AIDS Conference (AIDS 2012) in Washington, D.C., by study co-chair Kenneth Mayer, M.D., medical research director for the Fenway Community Health Center in Boston.
The HPTN 061 study, which involved 1,553 black MSM ages 18 and older in Atlanta, Boston, Los Angeles, New York, San Francisco and Washington, D.C., found a 2.8 percent overall rate of new HIV infections (known as HIV incidence) among the study population. Moreover, the researchers found a 5.9 percent HIV incidence rate among individuals 18 to 30 years of age.
MSM of all races and ethnicities are most heavily affected by HIV/AIDS in the United States., accounting for 61 percent of all new infections in 2009, according to the U.S. Centers for Disease Control and Prevention (CDC). Further, CDC data indicate that young black MSM (those aged 13 to 29 years old) had a 48 percent increase in new HIV infections from 2006 to 2009.
In addition to incidence data, early study analyses found that HIV infection was associated with high rates of untreated sexually transmitted infections (STIs) and poverty. Ninety-seven percent of study participants agreed to HIV testing. Of the study participants who self-reported as being HIV-uninfected or did not know their status, 12 percent (165 men) proved to be infected at time of enrollment. All participants who were HIV-infected at entry into the study, or who became infected while in the study, were referred for medical care and treatment.
The HPTN 061 study is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. It was conducted by the NIH-funded HIV Prevention Trials Network (HPTN).
NIAID Director Anthony S. Fauci, M.D., and Carl W. Dieffenbach, Ph.D., director of NIAIDís Division of AIDS, are available to comment on the HPTN 061 findings presented today.
To schedule interviews, please contact Kathy Stover, (301) 402-1663, email@example.com.
FOR MORE INFORMATION:
Information about the HPTN 061 study is available at www.clinicaltrials.gov under the identifier NCT0095129 and on the HPTN website. The study was funded through grant number 1U01AI068619 to the HPTN.
The AIDS 2012 conference is being held July 23-27, 2012, at the Walter E. Washington Convention Center in the District of Columbia. For more information about the AIDS 2012 meeting, please see www.aids2012.org/.
No comments have been made.
|Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.|